NCT03662776View on ClinicalTrials.gov

Effect of Treatment Modality on Psychosocial Functioning of Survivors of Unilateral Retinoblastoma

Enrolling by invitationOBSERVATIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2018

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Survivors of Unilateral Retinoblastoma
Interventions
BEHAVIORAL

BASC-3 survey

A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.

BEHAVIORAL

PROMIS survey

A comprehensive questionnaire, incorporating the BASC-3 and PROMIS measures, will be administered to parents of participants ages 8-17. The BASC-3 and PROMIS scales each have a parent and child version; these scales will be used to measure the secondary objective of parent and patient concordance rates for all participants ages 8 and older.

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

Texas Children's Hospital (Data Collection), Houston

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER